Sanuwave Health (NASDAQ:SNWV) Upgraded to "Strong-Buy" at Northland Capmk
Northland Capital Markets upgraded Sanuwave Health (NASDAQ:SNWV) to a "strong-buy" rating. Other brokerages have also rated the stock positively, with a consensus rating of "buy" and an average price target of $55.00. Sanuwave Health's stock opened at $38.81, with a 52-week range of $5.21 to $46.58. The company reported a quarterly EPS of $0.01, exceeding estimates. Institutional investors hold 42.53% of the stock, indicating strong interest in the company.
Sanuwave Health (NASDAQ:SNWV - Get Free Report) was upgraded by investment analysts at Northland Capmk to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.
A number of other brokerages have also weighed in on SNWV. Northland Securities started coverage on Sanuwave Health in a research report on Wednesday. They set an "outperform" rating and a $55.00 price objective on the stock. Wall Street Zen raised Sanuwave Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Finally, Roth Capital boosted their price objective on Sanuwave Health from $54.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $55.00.
Get Sanuwave Health alerts:
View Our Latest Research Report on SNWV
Sanuwave Health Price Performance
Sanuwave Health stock opened at $38.81 on Wednesday. Sanuwave Health has a 52 week low of $5.21 and a 52 week high of $46.58. The firm has a market cap of $332.60 million, a PE ratio of -4.70 and a beta of 1.39. The stock's fifty day simple moving average is $37.20.
Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.10. The business had revenue of $10.16 million for the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.
Institutional Investors Weigh In On Sanuwave Health
Hedge funds and other institutional investors have recently modified their holdings of the company. Solas Capital Management LLC bought a new stake in shares of Sanuwave Health during the first quarter valued at approximately $20,658,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Sanuwave Health during the first quarter valued at approximately $47,000. AWM Investment Company Inc. bought a new stake in shares of Sanuwave Health during the first quarter valued at approximately $18,153,000. Rhumbline Advisers bought a new stake in shares of Sanuwave Health during the second quarter valued at approximately $211,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Sanuwave Health during the second quarter valued at approximately $126,000. Institutional investors own 42.53% of the company's stock.
About Sanuwave Health
(Get Free Report)SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.
Read More
- Five stocks we like better than Sanuwave Health
- Upcoming IPO Stock Lockup Period, Explained
- Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now
- What is the Hang Seng index?
- Alphabet Stock Surges After Dodging Harsh Antitrust Remedies
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Qualcomm Is Outperforming NVIDIA After Months of Lagging
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Sanuwave Health Right Now?
Before you consider Sanuwave Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanuwave Health wasn't on the list.
While Sanuwave Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
